Clinical Trial

A Study of IBI3031 in Participants With Thyroid Eye Disease

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, randomized, double-masked, placebo-controlled, single/multiple-dose-escalation trial conducted in Chinese participants with Thyroid Eye Disease (TED), aiming to evaluate the safety and tolerability of IBI3031 administered via subcutaneous or intravenous injection.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-15
Trial Details
NCT Number NCT07622368
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Thyroid Eye Disease
Enrollment 66 participants
Start Date 2026-06-30
Primary Completion 2027-06-15 (estimated)
Study Completion 2027-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-14